Akt Inhibitor (Akti-1/2), Akt1/2 kinase inhibitor (ab142088)
Key features and details
- Potent isozyme selective Akt1/2 kinase inhibitor
- CAS Number: 612847-09-3
- Purity: > 99%
- Soluble in DMSO to 10 mM
- Form / State: Solid
- Source: Synthetic
製品の概要
-
製品名
Akt Inhibitor (Akti-1/2), Akt1/2 kinase inhibitor -
製品の詳細
Potent isozyme selective Akt1/2 kinase inhibitor -
別名
- Akti-1/2
-
生理活性の詳細
Potent isozyme selective Akt1/2 kinase inhibitor. (IC50 values are 58, 210 nM and 2.12 mM for Akt1, Akt2, and Akt3, respectively). No inhibition against pleckstrin homology (PH) domain-lacking Akts, PKA, PKC and SGK.
-
精製度
> 99% -
CAS 番号
612847-09-3 -
構造式
製品の特性
-
体系名
3-[1-[[4-(7-Phenyl-3H-imidazo[4,5-g]quinoxalin-6-yl)phenyl]methyl]piperidin-4-yl]-1H-benzimidazol-2-one -
分子量
551.65 -
分子式
C34H29N7O -
PubChem 登録番号
10196499 -
保存方法
Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
溶解性
Soluble in DMSO to 10 mM -
使用に関する注意
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES 線形表記
C1CN(CCC1N2C3=CC=CC=C3NC2=O)CC4=CC=C(C=C4)C5=NC6=CC7=C(C=C6N=C5C8=CC=CC=C8)N=CN7 -
由来
Synthetic
-
研究分野
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
参考文献 (18)
ab142088 は 18 報の論文で使用されています。
- Xu P et al. Hypoxia-mediated YTHDF2 overexpression promotes lung squamous cell carcinoma progression by activation of the mTOR/AKT axis. Cancer Cell Int 22:13 (2022). PubMed: 34996459
- Mao XQ et al. RNA-seq and ATAC-seq analyses of multilineage differentiating stress enduring cells: Comparison with dermal fibroblasts. Cell Biol Int 46:1480-1494 (2022). PubMed: 35673985
- Tang W et al. Suppression of CX3CL1 by miR-497-5p inhibits cell growth and invasion through inactivating the ERK/AKT pathway in NSCLC cells. Cell Cycle 21:1697-1709 (2022). PubMed: 35485293
- Afsar SY et al. Sphingosine-1-phosphate-lyase deficiency affects glucose metabolism in a way that abets oncogenesis. Mol Oncol 16:3642-3653 (2022). PubMed: 35973936
- Kataoka S et al. The costimulatory activity of Tim-3 requires Akt and MAPK signaling and its recruitment to the immune synapse. Sci Signal 14:N/A (2021). PubMed: 34131021